Premium
First‐trimester maternal serum alpha‐fetoprotein and human chorionic gonadotropin screening for chromosome defects
Author(s) -
Nebiolo Linda,
Ozturk Mehmet,
Brambati Bruno,
Miller Susan,
Wands Jack,
Milunsky Aubrey
Publication year - 1990
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/pd.1970100905
Subject(s) - amniocentesis , trisomy , chorionic villus sampling , human chorionic gonadotropin , aneuploidy , obstetrics , fetus , medicine , chorionic villi , down syndrome , gynecology , gonadotropin , pregnancy , alpha fetoprotein , andrology , prenatal diagnosis , chromosome , biology , endocrinology , genetics , hormone , psychiatry , gene , hepatocellular carcinoma
The aim of this study was to determine the efficacy of combined maternal serum alpha‐fetoprotein (MSAFP) and maternal serum human chorionic gonadotropin (MShCG) screening in detecting chromosome defects in the first trimester of pregnancy. Sera of 492 women (previously assayed for MSAFP) were analysed for MShCG under code without knowledge of cytogenetic results. Overall, 48 of 492 patients (9·8 per cent) had either an MSAFP multiple of the median ⩽0·5 or an MShCG β/ a z ratio multiple of the median ⩽ 0·25, eight of whom had a fetus with a serious chromosome defect. A third of fetuses with Down' s syndrome and 83 per cent with trisomy 18 were detected at a potential‘cost’ of providing chorionic villus sampling or amniocentesis in 8·6 percent of women screened.